News14 min
ICOTYDE (Icotrokinra): The First Oral Peptide FDA-Approved for Psoriasis — And Why It Matters Beyond Skin
On March 18, 2026, the FDA approved something that dermatologists have wanted for decades: a once-daily pill that clears psoriasis as effectively as injectable biologics. ICOTYDE is a cyclic peptide that blocks the IL-23 receptor — and it's just the beginning of what oral peptides could do for autoimmune disease.
Immune Modulation